US6701002056
US6701002056
Novo Nordisk A/S
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 70/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±39.0% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).
Beta (Market Relation)
0.38x
DefensiveVolatility (5Y p.a.)
39.0% p.a.
5-Year HorizonMax Drawdown (5Y)
-76.0%
5-Year HorizonSharpe Ratio
-0.19
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -36% |
| 3 Years | 43.2% | -76.0% | -0.65 | -25.4% |
| 5 Years | 39.0% | -76.0% | -0.19 | -4.9% |
| 10 Years | 32.8% | -76.0% | 0.12 | +6.5% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Elevated Short-Term Volatility: 3Y volatility (43.2%) is noticeably higher than the 5Y average (39.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -76.0% in the extended horizon.